CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Camp4 Therapeutics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$3.14−0.03 (-0.95%)
Close on Oct 19, 2026
- Market cap
- $181.90M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Camp4 Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Market Cap | $197.05M | $164.85M |
| Enterprise Value | $110.65M | $87.06M |
| PS Ratio | 46.74 | 3.60 |
Enterprise value
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 26.24 | 2.43 |
Income (trailing twelve months)
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Revenue | $4.22M | $57.94M |
| Operating Income | -$52.88M | -$21.44M |
| Net Income | -$107.24M | -$22.46M |
| EBITDA | -$51.09M | -$16.91M |
| EPS (Diluted) | -$2.20 | -$0.83 |
Margins
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -1254.2% | -44.5% |
| Profit Margin | -2543.7% | -39.2% |
| EBITDA Margin | -1211.7% | -31.3% |
| FCF Margin | -681.2% | -8.85% |
Returns
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -545.9% | -53.1% |
| Return on Assets (ROA) | -148.2% | -41.0% |
| Return on Capital Employed (ROCE) | -71.2% | -37.8% |
Growth
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 40.2% | 6.01% |
Balance sheet
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $86.40M | $62.42M |
| Net Cash (Debt) | $86.40M | $15.68M |
| Net Cash Per Share | $1.38 | $0.66 |
| Equity (Book Value) | -$693.00K | $48.79M |
| Book Value Per Share | -$0.01 | $1.36 |
| Tangible Book Value | -$693.00K | $23.06M |
| Working Capital | $70.89M | $75.77M |
Financial position
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.70 | 3.30 |
| Quick Ratio | 4.51 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$28.59M | -$12.35M |
| Capital Expenditures | -$129.00K | -$1.06M |
| Free Cash Flow | -$28.72M | -$20.28M |
| FCF Per Share | -$0.46 | -$0.42 |
Efficiency
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.06 | 0.38 |
| Revenue Per Employee | $87.83K | $398.96K |
| Profits Per Employee | -$2.23M | -$703.34K |
| Employee Count | 48 | 74 |
Dividends and yields
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -54.4% | -22.7% |
| FCF Yield | -14.6% | -9.07% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 62,753,200 | 58,179,650 |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 49,136,700 | 49,173,100 |
| Shares Held by Insiders | 21.7% | 11.6% |
| Shares Held by Institutions | 66.5% | 59.4% |
Taxes
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Camp4 Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -4.81 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Camp4 Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.